Eisai Co., Ltd

ISIN US2825793092 Symbol ESALY Industry Drug Manufacturers-Specialty & Generic Sector Healthcare
Eisai Co Price
83.59USD 1.47%
1y Low: 63.9
1y High: 102.2
1y Low: 63.9
1y High: 102.2
eisai.co.jp
Market Cap
19.3 B USD
Dividend Yield
2.2%
Performance 1y
6.66 %
PER
22.3

Eisai Co Stock Chart

Eisai Co Dividend Chart

Eisai Co Dividend Calendar

Year # Div. Div. Paid Div. Yield Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
2021 0 0 USD 0.6 %
2020 1 0.74 USD 1.1 %
2019 2 1.48 USD 2.0 %
2018 2 1.35 USD 1.8 %
2017 2 1.34 USD 2.3 %
2016 2 1.36 USD 2.6 %
2015 2 1.22 USD 2.1 %
2014 2 1.39 USD 4.1 %
2013 2 1.47 USD 4.6 %
2012 2 1.87 USD 5.8 %
2011 2 1.88 USD 6.9 %
2010 2 1.72 USD 7.7 %
2009 2 1.52 USD 7.1 %
2008 2 1.28 USD 5.8 %
2007 2 1.12 USD 5.3 %
2006 2 0.90 USD 3.2 %
2005 2 0.70 USD 3.2 %
2004 2 0.36 USD 2.2 %
2003 2 0.29 USD 2.1 %
2002 2 0.26 USD 2.4 %
2001 1 0.10 USD 0.8 %

Eisai Co Performance

1 Week
1 Month
6 Months
21.02 %
Year to Date
18.63 %
1 Year
6.66 %
5 Years
42.27 %

Eisai Co Revenue, EBIT, and Income

Eisai Co Margins

Eisai Co Shares Outstanding

Useful Links

Search Twitter: $ESALY, #ESALY

Eisai Co Company Info

Eisai Co., Ltd. offers pharmaceutical products in Japan. It offers Aricept for the treatment of alzheimer's disease/dementia with Lewy bodies; Methycobal for the treatment of peripheral neuropathy; and Fycompa, an antiepileptic drug for the adjunctive treatment of partial-onset and primary generalized tonic-clonic seizures. The company also provides Lyrica for pain treatment; Dayvigo, an anti-insomnia drug for the treatment of adults with insomnia; Lenvima, an anticancer agent/molecular targeted medicine for the treatment of thyroid cancer, renal cell carcinoma in combination with everolimus, and hepatocellular carcinoma; and Halaven, an anticancer agent/microtubule dynamics inhibitor for the treatment of breast cancer and liposarcoma. In addition, it offers Pariet, a proton-pump inhibitor for the treatment of gastric and duodenal ulcers, reflux esophagitis, and eradication of Helicobacter pylori infections, etc.; Humira, a fully human anti-TNF-a monoclonal antibody for the treatment of autoimmune diseases, such as rheumatoid arthritis; and Chocola BB plus, a vitamin B2 preparation for rough skin and stomatitis, as well as various products, which include third-class OTC drugs, designated quasi-drugs, and food with nutrient function. Eisai Co., Ltd. has a research collaboration agreement with Wren Therapeutics Ltd. for the discovery of small molecules that target synuclein for the potential treatment of synucleinopathies, including Parkinson's disease and dementia with Lewy bodies. The company was formerly known as Nihon Eisai Co., Ltd. and changed its name to Eisai Co., Ltd. in 1955. Eisai Co., Ltd. was founded in 1941 and is headquartered in Tokyo, Japan.

Eisai Co Price to Earnings Ratio (PE Ratio): 22.3

The current Price to Earnings Ratio of Eisai Co is 22.3.
The PE Ratio is calcluated by dividing the current Eisai Co share price (83.59 USD) by the earnings per share (3.0).

Eisai Co Dividend Yield: 2.2%

The current Dividend Yield of Eisai Co is 2.2%.

Eisai Co Market Cap: 19.3 B USD

The current market cap of Eisai Co is 19.3 B USD.

Eisai Co Stock Price: 83.59 USD

The current stock price of Eisai Co is 83.59 USD.

Eisai Co ISIN: US2825793092

The ISIN (International Securities Identification Number) of Eisai Co is US2825793092.

Eisai Co Ticker Symbol: ESALY

The ticker symbol of Eisai Co is ESALY.

Eisai Co Address

The address of the Eisai Co HQ is 4-6-10, Koishikawa, 112-8088 Tokyo.